ZSCO Invests 790 m RMB in Guobang Pharma, Launches Strategic Partnership
Zhejiang State‑owned Capital Operation Co., Ltd. (ZSCO) and Guobang Pharmaceutical (SHA: 605507) announced a strategic...
Company
CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small‑molecule, SYH2066, has been...
Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis
China‑based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection...
HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
China‑based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has...
Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS
China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody‑drug conjugate...
Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant is reportedly in exploratory talks...
Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...
BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
A leaked internal email from US major Bristol-Myers Squibb (BMS; NYSE: BMY) has recently surfaced...
CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced today that Anbenitamab Antibody Injection (KN026), co‑developed with Alphamab...
BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
BioNTech SE (NASDAQ: BNTX) and Bristol-Myers Squibb (BMS, NYSE: BMY) disclosed interim data from a...
Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
Summit Therapeutics (NASDAQ: SMMT) disclosed longer‑term progression‑free survival (PFS) data from its HARMONi trial of...
Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma
Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4 million milestone payment...
FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements
The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration...
MSD scrapes £1 billion UK expansion, shifts life‑science research to the US
US‑based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the cancellation of...
FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration
Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...
Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus
China‑based Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...
GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B
China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...
Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...
YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...
Novartis Secures Tabrecta Approval in China for METex14 NSCLC
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib...